Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Main Street Capital

Stocks Showing Improved Relative Strength: Main Street Capital

Main Street Capital shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Stocks Showing Improved Relative Strength: Main Street Capital

Stocks Showing Improved Relative Strength: Main Street Capital

A Relative Strength Rating upgrade for Main Street Capital shows improving technical performance. Will it continue?

Investors Business Daily

Stocks Showing Improved Relative Strength: Main Street Capital

Stocks Showing Improved Relative Strength: Main Street Capital

A Relative Strength Rating upgrade for Main Street Capital shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stocks With Rising Relative Strength: Main Street Capital

Main Street Capital shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Stocks With Rising Relative Strength: Main Street Capital

A Relative Strength Rating upgrade for Main Street Capital shows improving technical performance. Will it continue?

Investors Business Daily

Main Street Capital Shows Rising Relative Strength; Still Shy Of Key Benchmark

A Relative Strength Rating upgrade for Main Street Capital shows improving technical performance. Will it continue?

Investors Business Daily

Main Street Capital Getting Closer To Key Technical Benchmark

Main Street Capital shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Main Street Capital Shows Improved Relative Strength; Still Shy Of Benchmark

Main Street Capital Shows Improved Relative Strength; Still Shy Of Benchmark

Main Street Capital shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Main Street Capital Stock Gets Relative Strength Rating Upgrade

Main Street Capital Stock Gets Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Main Street Capital shows improving technical performance. Will it continue?

Investors Business Daily

Main Street Capital Stock Edges Higher With 96 Composite Rating

Main Street Capital Stock Edges Higher With 96 Composite Rating

Main Street Capital saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Main Street Capital's Earnings Outlook

Main Street Capital's Earnings Outlook

Main Street Capital (NYSE:MAIN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Main Street Capital will report an earnings per share (EPS) of $0.70.

Main Street Capital Earnings Conference Call Is Coming Up, Here's What You Need To Know

Main Street Capital Earnings Conference Call Is Coming Up, Here's What You Need To Know

Main Street Capital (NYSE:MAIN) will host a conference call at 10:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Main Street Capital (MAIN) Conference Call Follow this link to access the live webcast.

Main Street Capital: Q4 Earnings Insights

Main Street Capital: Q4 Earnings Insights

Main Street Capital (NYSE:MAIN) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD 50 Growth Stocks To Watch: Main Street Capital Poised For Green Light

Main Street Capital is a growth stock to watch as its stock nears a buy point as continue to rebound from Covid issues.

Organisations

Investor Business Daily

Western Digital

Canaccord Genuity

Rhythm Pharmaceuticals

BioCryst Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play